MALDI-MS Protein Profiling of Chemoresistance in Extracellular Vesicles of Cancer Cells

Significance of the Topic

The rapid and minimally invasive detection of chemoresistance biomarkers is critical for optimizing cancer treatment and improving patient survival. Extracellular vesicles (EVs) released by tumor cells carry protein signatures that reflect the cellular response to chemotherapy agents such as 5-fluorouracil. Profiling these vesicles by MALDI-TOF mass spectrometry offers a promising liquid biopsy approach to monitor therapy resistance without the need for invasive tissue sampling.

Study Objectives and Overview

This study aimed to apply MALDI-TOF MS protein profiling to EVs derived from colon cancer cell lines with increasing levels of resistance to 5-fluorouracil (5, 25, and 125 µM). The goal was to identify discriminant protein patterns associated with chemoresistance and validate the method as a rapid tool for biomarker discovery in liquid biopsy samples.

Methodology

EVs were isolated from culture supernatants by sequential ultracentrifugation (500 g, 16 500 g, 120 000 g) and prepared with α-cyano-4-hydroxycinnamic acid matrix. Protein mass spectra were acquired over m/z 2 000–25 000 using a MALDI-8020 MALDI-TOF-MS system. Data processing and multivariate analysis, including hierarchical clustering and PLS-DA, were performed with eMSTAT Solution software to differentiate EV profiles from naïve and 5-fluorouracil-resistant cell subclones.

Used Instrumentation

• Shimadzu MALDI-8020 MALDI-TOF-MS system
• α-Cyano-4-hydroxycinnamic acid (CHCA) matrix
• Ultracentrifugation equipment for EV isolation
• eMSTAT Solution multivariate analysis software

Main Results and Discussion

Spectra from EV samples demonstrated reproducible peaks in the m/z 2 000–7 000 range that correlated with levels of 5-fluorouracil resistance. PLS-DA score plots revealed clear separation between naïve and resistant groups, with higher drug concentrations exhibiting distinct protein signatures. Sensitivity of the assay reached the low µg/mL protein range, corresponding to ~1.2–5×10¹⁰ particles/mL, adequate for potential clinical liquid biopsy applications.

Benefits and Practical Applications

• Non-invasive monitoring of chemoresistance via EV profiling
• Rapid analysis without the need for extensive sample preparation
• Potential integration into clinical workflows for early detection of therapy failure
• Scalability for high-throughput screening of patient samples

Future Trends and Applications

Advances in MALDI-TOF instrumentation sensitivity and software algorithms are expected to enhance detection limits and classification accuracy. Integration with other omics platforms and standardized EV isolation protocols may broaden the scope of liquid biopsy diagnostics. In the long term, real-time monitoring of therapy response through point-of-care MALDI-MS devices could guide personalized chemotherapy regimens.

Conclusion

This study demonstrates that MALDI-TOF MS profiling of extracellular vesicles, combined with multivariate analysis, is a powerful approach for identifying chemoresistance biomarkers. The workflow offers a fast, minimally invasive means to monitor treatment response in cancer patients and holds promise for clinical translation.

References

1. Stübiger G. et al. MALDI-MS Protein Profiling of Chemoresistance in Extracellular Vesicles of Cancer Cells. Analytical Chemistry. 90, 13178–13182 (2018).